CRDF
- Cardiff Oncology, Inc.
()
Overview
Company Summary
Cardiff Oncology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of cancer. Specifically, the company is dedicated to targeting complex mutations and promoting the eradication of cancerous cells and tumors.
Cardiff Oncology harnesses its expertise in genetics and molecular biology to identify and develop novel drug candidates that target specific genetic alterations observed in certain types of cancer. By focusing on these genetic alterations, the company aims to address significant unmet medical needs and improve patient outcomes.
The company's lead product candidate is known as onvansertib, which is being investigated for its therapeutic potential in treating various forms of cancer, including acute myeloid leukemia (AML), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer. Onvansertib is designed to inhibit the activity of key cell division proteins, thereby disrupting cancer cell growth and promoting cancer cell death.
Cardiff Oncology also conducts preclinical research to discover additional drug candidates and expand its pipeline. By leveraging its scientific expertise and strategic collaborations, the company strives to advance innovative oncology treatments that can make a meaningful impact on patients' lives.
It is important to note that the above information is a general overview of Cardiff Oncology's activities, and specific details about the company's research, clinical trials, and product development can be obtained from their official website or through regulatory filings.